OPAN-OTOL-MSOIA-BGMisms

Wednesday, 13 May 2026

P GENERATION STUDY

Based on the presentation slide "Generation study" in image_3b3a94.png, here are the take-home messages (THM) regarding the Newborn Genomes Programme:

1. Scope and Scale of the Study

WGS Testing: The study uses Whole Genome Sequencing (WGS) to test for 480 genetic diseases.
Focus on Immunology: Immune disorders are a significant focus, accounting for 25% of the conditions being tested.
Recruitment Goal: The programme aims to recruit 100,000 infants.
Timeline: The study is scheduled to run until March 2027.

2. Principles for Condition Selection

Conditions included in the screening are chosen based on four strict guiding principles:

Reliability: There must be strong evidence that the genetic variant causes the condition and can be reliably detected.
Clinical Impact: A high proportion of individuals with the variant would be expected to have symptoms that significantly impact their quality of life if left undiagnosed.
Effective Intervention: Early intervention must be proven to substantially improve patient outcomes.
Equitable Access: Screening is only performed for conditions where the necessary interventions are equitably accessible to all patients.

3. Programme Objectives

The "Newborn Genomes Programme," as depicted in image_3b3a94.png, represents an NHS-embedded effort to move toward predictive and preventative healthcare through genomic innovation.

P SCID

Based on the presentation slide "Importance of early diagnosis and treatment" in image_3b9b98.png, the take-home messages (THM) regarding Severe Combined Immunodeficiency (SCID) are:

1. Impact of Early Diagnosis on Survival

Proband vs. Sibling Outcomes: Probands (typically diagnosed after becoming symptomatic) have an overall survival rate of only 40%.
Early Detection Benefit: Siblings (often diagnosed earlier due to family history) have a significantly higher overall survival rate of 90%.
Pre-treatment Mortality: 35% of probands die before they can even reach Hematopoietic Stem Cell Transplant (HSCT), compared to only 1.7% of siblings.

2. Critical Timing for Treatment

The timing of HSCT is a primary determinant of survival:

Under 3.5 Months: Achieving HSCT before 3.5 months of age results in a 95% survival rate.
Over 3.5 Months: Survival drops to 76% if HSCT occurs after 3.5 months.

3. Risks of Delayed Diagnosis

Delaying diagnosis and treatment increases the risk of life-threatening complications, including:

Infection: Acquisition of opportunistic pathogens.
Respiratory Viral Infection: Having a respiratory viral infection prior to HSCT leads to a 59% mortality rate.
Clinical Decline: Progressive Failure to Thrive (FTT).
Transfusion Risks: Inadvertent transfusions can lead to Graft-Versus-Host Disease (GVHD).

Summary Comparison Table

Metric	Probands (n=48)	Siblings (n=60)
Death before HSCT	35%	1.7%
Overall Survival	40%	90%
Overall Mortality	60%	10%

Based on the presentation slide "SCID Newborn Screening" in image_3b97d1.png, here are the take-home messages (THM) regarding the impact and evaluation of Severe Combined Immunodeficiency (SCID) screening in the UK:

1. Screening Efficacy and Survival Outcomes

Dramatic Survival Increase: The survival rate for infants identified with SCID through screening was 92% ( $11/12$ ), compared to only 20% ( $2/7$ ) in the non-screened cohort.
Identification Gap: Screening identified cases that would have otherwise been missed; of the 12 children found to have SCID via screening, only 2 would have been identified through family history or targeted screening alone.
UK Incidence: The incidence of SCID in the UK is approximately 1 in 50,000 live births.

2. UK In-Service Evaluation Details

Implementation: A UK in-service evaluation began in September 2021.
Coverage: The evaluation covers approximately $2/3$ of England, while $1/3$ is currently not included.
Vaccination Protocol: SCID screening requires the delay of the BCG vaccine to 28 days of age.

3. Screening Results and "Flagged" Cases

Positivity Rate: 568 children were flagged as "positive," representing a ratio of 1:1680 infants screened.
Demographics and Accuracy:
- 23% of those flagged were under 28 weeks gestation.
- 56% of flagged infants actually had normal immunology testing upon clinical review, which usually occurs the next working day.
Abnormal Results Breakdown: Of the remaining 252 with abnormal testing, 76 died before further testing due to prematurity, and 12 were confirmed to have SCID.

Screening vs. Non-Screened Survival Comparison

Cohort	Identified with SCID	Survival Rate
Screened	12 infants	92%
Non-Screened	7 infants	20%

refers to image_3b97d1.png.